내과 R2 이지영. INTRODUCTION  Asthma  Allergic airway inflammation,Th2-weighted process  Biomarkers  Phenotypic distinctions  Development of personalized.

Slides:

Advertisements

Similar presentations

Asthma Update Dr Ed Cetti Consultant Respiratory Physician Spire Gatwick Park Hospital Surrey & Sussex Healthcare NHS Trust.

Advertisements

A. Nakonechna 1, J. Antipkin 2, T. Umanets 2, V. Lapshyn 2 1) Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom.

Professor of Respiratory Medicine

Clinical Observation of Montelukast as a Partner Agent for Complementary Therapy.

Prof. Dr. U. Wahn Long term use of omalizumab – Is the IgE response modified? Ulrich Wahn Department of Pediatric Pneumology and Immunology.

Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.

UPMC Chair in Translational Airway Biology

Upper Airways Research Laboratory Department of Otorhinolaryngology Advanced treatments of nasal polyposis: Anti-IL-5 and Anti-IgE Which for whom? Prof.

Asthma and Pregnancy Michael Schatz, MD, MS Chief, Department of Allergy Kaiser-Permanente Medical Center San Diego, CA.

Impact of Montelukast on Symptoms of Mild-to-Moderate Persistent Asthma and Exercise-Induced Asthma: The ASTHMA Survey The ASTHMA* survey was supported.

Pulmonary-Allergy Drugs Advisory Committee January 17, FLOVENT ® DISKUS ® NDA , S004 GlaxoSmithKline Pulmonary-Allergy Drugs Advisory Committee.

Anti-IgE in Asthma and Other Allergic Diseases Harold S. Nelson. MD Professor of Medicine National Jewish Health And University of Colorado School of Medicine.

Tips for Caring for Patients with Reactive Airways Jason E. Knuffman, MD Allergy October 27, 2004.

Asma na Infância Renato T. Stein, M.D. Pontifícia Universidade Católica Porto Alegre, Brazil.

FDA Advisory Committee May 15, 2003 Genentech Marketing Application STN / 0 Omalizumab Recombinant human anti-IgE for treatment of asthma Efficacy.

氣喘: 風雲再起 Asthma: an old disease, a new challenge of future

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Asthma control test (ACT) scores and FeNO correlation

Anti-IgE Use in Allergy

Immune responses that are inadequately controlled, inappropriately targeted to host tissues, or triggered by commensal microorganisms or usually harmless.

Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma Stephen P. Peters, M.D., Ph.D., Susan J. Kunselman, M.A., Nikolina Icitovic, M.A.S.,

Pharmacologic Treatment Of Asthma 1 د. ميريانا البيضة.

내과 R2 이지훈 N Engl J Med Sep 8.

Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.

Linda Rogers and Joan Reibman Curr Opin Pulm Med. (2012) January Vol. 18 Stepping down asthma treatment: how and when Journal club R4. Yoo,

The Use of Fraction of Exhaled Nitric Oxide in Pulmonary Practice Kaiser G. Lim, MD, FCCP; and Carl Mottram, RRT, RPFT CHEST 2008; 133:1232–124 Jeung Eun.

1 Once-daily indacaterol versus twice-daily salmeterol for COPD ; a placebo-controlled comparison R2 정명화 Eur Respir J 2011; 37: 273–279.

Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Comparison of Physician-, Biomarker-, and Symptom-Based.

GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.

Asthma Management What is New? Prof: Samiha Ashmawi Professor of Chest Diseases Ain Shams University.

Biologics in Asthma—The Next Step Toward Personalized Treatment

Increased Exhaled Nitric Oxide and Risk of Loss of Control in Children Undergoing Clinical Asthma Remission D.V. Chang, J.E. Balinotti, C. Castro Simonelli,

Once-daily tiotropium add-on to at least ICS improves control and reduces exacerbation risk in symptomatic asthma, independent of serum IgE or blood.

Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity Andrei Malinovschi,

Asthma Yardstick Annals of Allergy, Asthma & Immunology

Blood eosinophil count and exacerbation risk in patients with COPD

Moderate-to-Severe Asthma Management

A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. GINA:

COPD by the Guidelines.

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Alalia Berry, MD, William W. Busse, MD

Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.

Volume 153, Issue 4, Pages (April 2018)

Asthma diagnosis and treatment: Filling in the information gaps

Combination Inhaled Therapy in COPD: The Impact of Recent Data

Severe Asthma in Primary Care: Identification and Management

Blood eosinophils as a marker of eosinophilic exacerbations in COPD

Asthma: A Highly Prevalent and Often Inadequately Controlled Disease

12 months before treatment 12 months after treatment

Jennifer L. Ingram, PhD, Monica Kraft, MD

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol Ian D. Pavord, DM, FRCP, Peter K. Jeffery,

Advances in Severe Asthma Management

Long-Acting Agents in Severe COPD

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Blood eosinophils predict therapeutic effects of a GATA3-specific DNAzyme in asthma patients Norbert Krug, MD, Jens M. Hohlfeld, MD, Roland Buhl, MD,

Peripheral blood eosinophil levels based on a threshold of (A) 150 cells/μL, patients not randomised to inhaled corticosteroids (ICS)-containing treatment.

Pinja Ilmarinen, PhD, Leena E

The efficacy and safety of omalizumab in pediatric allergic asthma

A) Total Asthma Quality of Life Questionnaire (AQLQ) score over 12 months after treatment with bronchial thermoplasty (BT) in the per protocol population.

Pathophysiologic Targets of Allergic Asthma

Therapeutic strategies to reduce asthma exacerbations

Efficacy and tolerability of antiasthma herbal medicine intervention in adult patients with moderate-severe allergic asthma Ming-Chun Wen, MD, Chun-Hua.

Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children Georgette Stern, MSc, Johan de Jongste, MD, Ralf.

Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.

Presentation transcript:

내과 R2 이지영

INTRODUCTION  Asthma  Allergic airway inflammation,Th2-weighted process  Biomarkers  Phenotypic distinctions  Development of personalized medicine  Predict responses to therapy  IgE  IL-4, IL-5, and IL-13 from Th2-type CD4+ cells  IgE class  Levels of cytokines are low & cannot be measured  IgE, not been predictive of response to anti-IgE therapy

INTRODUCTION  Three biomarkers  Fractional exhaled nitric oxide (FENO)  From IL-13  Clinical use by American Thoracic Society (ATS)  Peripheral blood eosinophils  Distinct phenotype (eosinophilic asthma)  Serum periostin  From airway epithelial cells in response to IL-13

INTRODUCTION  Omalizumab (Xolair)  Recombinant humanizedmonoclonal antibody that selectively binds to free IgE  Moderate-to-severe persistent allergic asthma (IgE-mediated), inadequately controlled with inhaled corticosteroids (ICS)  EXTRA study  Potential of 3 biomarkers to predictors  Therapeutic benefit of omalizumab

Method HighLow FeNO ≥19.5 ppb<19.5 Peripheral blood eosinophil count ≥260/ul<260/ul Serum periostin levels ≥50ng/ml<50ng/ml  12–75 years of age & history of severe persistent allergic asthma for more than 1 year  Randomized to omalizumab or placebo for 48wks (+ high-dose ICS and LABA, with or without controller medications)  Cut off

Method  Treatment effect  48-week treatment period  Exacerbations: Requiring systemic corticosteroids for >3 d or increase of >20 mg in the average daily OCS dose  Secondary efficacy endpoints  Asthma symptom score  Albuterol use  Asthma quality of life questionnaire (AQLQ)  % predicted FEV1

Results

 Evaluation of patterns of treatment effect for varying levels of each biomarker  Time to first protocol-defined exacerbation

Results  Evaluation of secondary endpoints.

Results  Safety  Treatment-emergent AEs was similar in the biomarker-low and biomarker-high subgroups

Conclusion Overall population of premenopausal women  The difference in exacerbation frequency between omalizumab and placebo was greatest in the three high-biomarker subgroups, probably associated with the greater risk for exacerbations in high subgroups.  Additional studies are required to explore the value of these biomarkers in clinical practice.